The surge in market valuation is largely fueled by the rapid adoption of GLP-1 and incretin injectables for obesity treatment, which currently outpaces existing manufacturing capacity. Simultaneously, stricter regulatory requirements—specifically EU GMP Annex 1 compliance—are compelling firms to invest heavily in isolator technology and Restricted Access Barrier Systems (RABS) to ensure global sterility standards.

Consumables continue to dominate the product landscape, accounting for 80.1% of the market share in 2025. Vials, syringes, and cartridges remain essential for maintaining product integrity, particularly for biologics and biosimilars. Meanwhile, Contract Manufacturing Organizations (CMOs) have emerged as the fastest-growing end-user segment. Pharmaceutical companies are increasingly outsourcing these operations to reduce costs and secure access to specialized aseptic filling expertise. Regionally, Europe leads the market with a 36.4% share, supported by a dense network of CDMOs and a robust infrastructure for high-end biopharmaceutical production.